摘要
目的:探讨分析采用中医治疗中晚期肺癌患者的临床价值。方法:选取2013年12月-2014年12月在我院就诊的37例中晚期肺癌患者,按照患者的入院就诊顺序将其随机分成观察组(在常规化疗基础上配合益肺散结方治疗)和对照组(单独采用常规化疗治疗),将两组患者的近期疗效、中医证候改善情况、生活质量改善情况以及不良反应发生率等进行对比分析。结果:观察组患者临床治疗总有效率为47.4%,对照组临床治疗总有效率为33.4%,观察组近期疗效明显优于对照组(P<0.05)。观察组中医证候改善有效率为84.2%,对照组中医证候改善有效率为66.7%,观察组患者中医证候改善情况明显优于对照组(P<0.05)。观察组生活质量总稳定率为84.2%,对照组生活质量总稳定率为61.1%,两组生活质量对比存在统计学意义(P<0.05)。两组患者均未出现严重的肝肾功能异常症状,但观察组治疗期间出现重度骨髓抑制、心肌缺血等不良反应发生率(21.1%),相对于对照组(50.0%)明显偏低(P<0.05)。结论:中晚期肺癌患者采用益肺散结方治疗的临床疗效确切,可显著改善患者的临床症状,有利于减轻用化疗药物治疗产生的副作用,能够提高患者的生活质量,是一种安全、有效的治疗方案,值得在临床上推广。
Objective： To investigate clinical values of TCM in advanced lung cancer. Methods： 37 patients were divided into the observation group （received the Yifei Sanjie prescription based on the conventional chemotherapy） and the control group （treated with the conventional chemotherapy only）. Results： The total efficiency was 47.4% in the observation group, and 33.4% in the control group. The recent efficacy in the observation group was much better. Improvement of TCM symptoms was 84.2% in the observation group, and 66.7% in the control group; the observation group was much better. Stable rate of quality of life in the observation group was 84.2%, better than 61.1% in the control group, with significant difference. All patients did not appear severe liver and kidney dysfunction symptoms. During the treatment, severe bone marrow suppression and myocardial ischemia were found in the observation group; the incidence was 21.1%, significantly lower than 50.0% in the control group （P〈0.05）. Conclusion： Treating advanced lung cancer with the Yifei Sanjie prescription showed aexact effect, with improving the clinical symptoms, reducing the side effects of chemotherapy drugs, improving the quality of life, was worthy of promotion.
出处
《中医临床研究》
2015年第29期41-43,共3页
Clinical Journal Of Chinese Medicine
关键词
中晚期肺癌
中医治疗
临床价值
Advanced lung cancer
TCM treatment
Clinical Value
